BUDAPEST, April 25. /TASS/. The International Weightlifting Federation (IWF) has decided not to suspend Lyaysan Makhiyanova, 2013 European Junior champion in 75kg and Russian champion, for using meldonium, the IWF press service said on Monday.
"The IWF reports that samples of Ms. Hripsime Khurshudyan (ARM), Ms. Lyaysan Makhiyanova (RUS), Mr. Krzysztof Szramiak (POL) have returned an Adverse Analytical Finding for (S4.5.3 Hormone and metabolic modulators) meldonium," the report said.
"The IWF decided not to suspend the aforementioned Athletes provisionally," the report added noting that "in any case where it is determined that the athletes did not commit an anti-doping rule violation, the relevant decisions will also be published."
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.
The drug meldonium (mildronate) was included in the list of preparations banned by the World Anti-Doping Agency from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
Earlier, WADA said that a total of 172 athletes had tested positive for meldonium. According to TASS sources at least 31 Russian athletes, including woman tennis player Maria Sharapova, woman swimmer Yulia Yefimova and speed skater Pavel Kulizhnikov, are suspected of using the prohibited medial formula.
Meldonium (contained in the drug called mildronate) is used in sports for enhancing the human body’s ability to resist physical strain during training sessions and nervous and psychological pressures during competitions. In the CIS countries it is used as a pre-emptive drug against cardiovascular diseases. The presence of this substance in the athlete’s doping sample during and between competitions has been regarded as a violation of doping rules since January 1, 2016.